603 filings
ARS
2023 FY
PLX
Protalix BioTherapeutics Inc.
17 May 24
Annual report to shareholders
5:05pm
DEFA14A
PLX
Protalix BioTherapeutics Inc.
17 May 24
Additional proxy soliciting materials
5:00pm
10-Q
2024 Q1
PLX
Protalix BioTherapeutics Inc.
Quarterly report
10 May 24
7:20am
8-K
PLX
Protalix BioTherapeutics Inc.
10 May 24
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
6:59am
DEF 14A
PLX
Protalix BioTherapeutics Inc.
Definitive proxy
29 Apr 24
4:30pm
8-K
5dz1z702xfqld8
14 Mar 24
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
6:57am
8-K
pl3dx03m
26 Dec 23
Protalix BioTherapeutics Issues 2024 Letter to Stockholders
6:56am
8-K
9qer gnjpfv
6 Nov 23
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
7:22am
8-K
jucc 1b32jfgg3fm
12 Sep 23
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
6:58am
S-8
cyk5jt 9o7r7ps9i
11 Aug 23
Registration of securities for employees
4:31pm
8-K
3dc xs004emp
7 Aug 23
Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results
6:59am
8-K
bedq6e s1d8jtdyq
13 Jul 23
Submission of Matters to a Vote of Security Holders
4:41pm
424B3
9prmokfa1dhy8
7 Jul 23
Prospectus supplement
4:30pm
8-K
rv4 6lw8146
29 Jun 23
Submission of Matters to a Vote of Security Holders
7:24am
DEFA14A
7i1l80yw
28 Jun 23
Additional proxy soliciting materials
4:30pm
8-K
llnjgdf7j62ko55 x80
30 May 23
Protalix BioTherapeutics Issues Letter to Stockholders
7:23am
ARS
d6nuopbff3e qn46b
19 May 23
Annual report to shareholders
4:56pm